From: The French glioblastoma biobank (FGB): a national clinicobiological database
Patients included in the FGB | Number | % |
---|---|---|
Patient characteristics | ||
Age (median age: 63 years) | ||
< 70 years | 801 | 73.7 |
≥ 70 years | 286 | 26.3 |
Sex | ||
Male | 653 | 60.1 |
Female | 434 | 39.9 |
KPS score | ||
≥ 70 | 601 | 55.3 |
< 70 | 73 | 6.7 |
Missing data | 413 | 38.0 |
Risk factors | ||
No relevant exposure | 549 | 50.5 |
Relevant exposure | 124 | 11.4 |
Family history of brain tumors | 46 | 4.2 |
Electromagnetic fields | 19 | 1.7 |
Petrochemical exposure | 16 | 1.5 |
Pesticide exposure | 55 | 5.1 |
Other (e.g. chemical products, asbestos, lead) | 42 | 3.9 |
Missing data | 414 | 38.1 |
OS | ||
Median (24.2 months) | 915 | 84.2 |
Short (< 6 months) | 100 | 9.2 |
Long (> 3 years) | 61 | 5.6 |
Missing data | 172 | 15.8 |
Tumor characteristics | ||
Tumor location | ||
Unilobar | 454 | 41.8 |
Frontal lobe | 166 | 15.3 |
Temporal lobe | 169 | 15.5 |
Parietal lobe | 91 | 8.4 |
Occipital lobe | 18 | 1.7 |
Corpus callosum | 8 | 0.7 |
Cerebellum | 2 | 0.2 |
Multilobar | 485 | 44.6 |
Missing data | 148 | 13.6 |
2016 WHO CNS classification | ||
GB IDH-wildtype | 937 | 86.2 |
Giant cell GB | 35 | 3.2 |
Gliosarcoma | 8 | 0.7 |
GB IDH-mutant | 62 | 5.7 |
GB NOS | 88 | 8.1 |
MGMT status | ||
Unmethylated | 209 | 19.2 |
Methylated | 201 | 18.5 |
Missing data | 677 | 62.3 |
First-line treatment | ||
Type of surgery | ||
Biopsy | 145 | 13.3 |
Surgical biopsy | 35 | 3.2 |
Stereotactic biopsy | 106 | 9.8 |
Missing data | 4 | 0.4 |
Resection [total, subtotal (≥ 90%) or partial (< 90%)] | 797 | 73.3 |
Lobectomy | 9 | 0.8 |
Missing data | 136 | 12.5 |
Surgical technique/per-operatory treatment | ||
Awake craniotomy | 67 | 6.2 |
5-ALA fluorescence | 78 | 7.2 |
Gliadel wafer | 67 | 6.2 |
Adjuvant therapy | ||
Without adjuvant therapy | 46 | 4.2 |
Radiotherapy alone | 25 | 2.3 |
Radiotherapy/TMZ | 624 | 57.4 |
Avastin (± radiotherapy/TMZ) | 45 | 4.1 |
Gliadel wafer (± radiotherapy/TMZ) | 65 | 6.0 |
Other chemotherapy | 18 | 1.7 |
Missing data | 177 | 16.3 |
Second-line treatment | ||
Surgery (± radio/chemotherapy) | 105 | 9.7 |
Treatment without surgery | 545 | 50.1 |